Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.48 |
| ▸ | THRA | P10827 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203752 | 0.88 | PPARA (0.43) | HPGDHSD17B10LMNAFFAR1KDM4E | |
| SCHEMBL2911933 | 0.87 | KAT6A (0.37) | PTGDR2THRATHRBMCL1HPGD | |
| SCHEMBL10203729 | 0.83 | FFAR1 (0.35) | MCL1HPGDLMNAFFAR1ALOX15 | |
| SCHEMBL10203743 | 0.82 | FFAR1 (0.39) | HPGDLMNAFFAR1KDM4EALDH1A1 | |
| SCHEMBL562863 | 0.81 | LMNA (0.41) | LMNAALOX15ALDH1A1 | |
| SCHEMBL10203746 | 0.80 | ALDH1A1 (0.41) | LMNAKDM4EALDH1A1 | |
| SCHEMBL561861 | 0.80 | FFAR1 (0.42) | FFAR1 | |
| SCHEMBL10203744 | 0.80 | FFAR1 (0.42) | THRAHPGDFFAR1ALOX15ALDH1A1 | |
| SCHEMBL562138 | 0.79 | SMN1; SMN2 (0.53) | PPARG | |
| SCHEMBL2914074 | 0.79 | CD274 (0.34) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | PTGDR2 2229/4885THRA 1072/4885THRB 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.